Temasek, Singapore""""s state-owned investment firm, has withdrawn from investing in the debt-laden Sanjiu Enterprise Group, the largest drugmaker in the mainland. "We""""re currently not in discussions with Sanjiu Enterprise over a possible investment," said a spokeswoman at Temasek, whose direct portfolio exposure to China amounted to S billion (HK.1 billion) by the end of October 2005. However, Sanjiu""""s Shenzhen-listed unit Sanjiu Medical and Pharmaceutical said in an announcement its parent is approaching potential investors, including Temasek, Hong Kong-listed Shanghai Industrial and privately owned Fosun Group. "But no formal document has been signed, and a detailed plan hasn""""t been decided," the statement said.
淡马锡退出三九收购
新加坡国有投资公司淡马锡退出对大陆最大的医药制造商负债的三九集团的投资。淡马锡的发言人表示，淡马锡现在没有与三九集团协商任何可能的投资。截至2005年10月底，淡马锡在中国的直接投资达到40亿美元。但是在深圳上市的三九医药在声明中表示，其母公司三九集团正在与潜在投资者协商，包括淡马锡，香港上市的上实集团和私营企业复星集团。但声明表示，还尚未签署任何正式文件，细节性的计划还在商讨中。
|
